Lifescient

Lifescient is a privately held biopharmaceutical company headquartered in Irvine, California, dedicated to optimizing drug delivery for improved patient outcomes. The company primarily utilizes the 505(b)(2) regulatory pathway to develop proprietary formulations of well-characterized drugs, with a focus on intranasal administration for Central Nervous System (CNS) disorders. Their core technology platform is designed to provide rapid drug absorption and consistent delivery, particularly for acute conditions where speed of onset is critical. Lifescient’s lead pipeline candidates include LS-101 for the treatment of migraine and LS-102 for seizure clusters. The management team consists of industry veterans with significant experience in pharmaceutical development and commercialization. By enhancing the delivery of established molecules, the company aims to reduce clinical risk and accelerate the delivery of therapeutic solutions to market.